VIVUS, Inc. (NASDAQ:VVUS) today sent a letter to its shareholders indicating First Manhattan Co’s campaign to replace Vivus’ existing board a serious threat.
The pharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health in its today’s letter to the shareholders, emphasized that there is no shortcut to unlock the value represented by Qsymia.
Qsymia Seen Slow Pick Up
Once touted
Setup a free account to get access to this article (no credit card required).Login required to continue reading.
Already a member? Log in here
